Human iPSC-derived Mesenchymal Stem Cells
Mesenchymal stem cells (“MSCs”) are non-haematopoietic, multipotent stromal stem cells that can differentiate into a variety of cell types, including: osteoblasts, chondrocytes, myocytes, and adipocytes. Tempo-iMSCTM are human iPSC-derived mesenchymal stem cells. Tempo-iMSCTM express cell surface markers such as CD73, CD90, CD166, and CD105, in addition to Oct4 and Nanog. This expression profile is predictive of the long-term proliferative capacity of cultured human MSCs (see reference: here). MSCs have immunomodulatory features, secrete cytokines and immune-receptors which regulate the microenvironment in the host tissue and they have multi-lineage potentials for a variety of cell types. MSCs can be used in a variety of screening applications, from screening biologics and small molecules to siRNAs. Due to MSCs’ ability to self-renew (= growth without differentiation), they are easily scalable for running large-scale assays.
NEW! For scientists working on exosomes, please email us for conditional media for exosome extractions and biomarker validations.
NEW! For scientists working on CD34+ HSCs, please email us regarding Tempo-iHSCTM (SKU214; Custom Requests Only).
Tempo-iMSC™ Immunocytochemistry: anti-human-Nanog (CST)
Tempo-iMSC™ Immunocytochemistry: anti-human-Oct4 (CST)
Tempo-iMSC™ RT-PCR data (left-to-right): CD90/Thy1, CD105, CD166, Oct4, Nanog
Tempo-iMSC™, monolayer, 9 days post-thaw
Tempo-iMSC™, monolayer, 10 days post-thaw
Tempo-iMSC™ are intended for basic scientific research, drug discovery and therapeutics development use only. It is not a product for human testing or diagnostics.
Biomarker discoveries and validations
In vitro assays using MSCs (e.g., cytokine release assays)
Large-scale compound screenings
Lineage differentiation studies
~1.25 x10^6 cells per 1ml of freezing medium (vial)
Long-term Storage: liquid nitrogen
Growth Properties: adherent monolayer
Storage: remove cryovials (dry ice packaging) and place the vial into liquid nitrogen for storage. Alternatively, thaw and use the cells immediately.
Technology used: in-house developed proprietary serum-free, virus-free, nucleic-acids-free, feeder-free, and integration-free technology.
Starting Materials: human dermal/fibroblast cells
QC: Sterility, Safety (BioSafety Level 2), HIV/viruses, bacteria, fungi: negative. Cell viability post-thawing (>90%)
Tempo-iMG™: Architectural Strategies
Tempo-iMG™ was cited in cell.com in a study that investigated HIV-1 integration in the unexplored microglia reservoir that gives rise to continued HIV replication in infected cells. Scientists used Tempo-iMG™ human iPSC-derived microglia to...
NASH – The Urgent Need for Better Disease Models and New Therapies
Welcome to our new mini-series about liver organoids. In Part 1, we focus on non-alcoholic steatohepatitis (NASH), a severe and prevalent form of non-alcoholic fatty liver disease for which no drugs have been approved. We look at the current...
Tempo Bioscience Expands Human Liver Models for Toxicity Evaluation and Disease Modeling
SAN FRANCISCO, CA —Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in...